Introduction {#Sec1}
============

Maturity onset diabetes of the young (MODY) is a hereditary form of diabetes with autosomal dominant inheritance and is characterized by onset at a young age and the presence of an initial defect of pancreatic β-cell function. This type of diabetes differs from classic types of diabetes mellitus---type 1 (DM1) and type 2 (DM2)---in disease progression, in treatment strategies, and prognosis \[[@CR1]\]. To date, 13 types of MODY (MODY1 through MODY13) have been identified, each associated with mutations in a specific gene: *HNF4A*, *GCK*, *HNF1A*, *PDX1*, *HNF1B*, *NEUROD1*, *KLF11*, *CEL*, *PAX4*, *INS*, *BLK*, *KCNJ11*, and *ABCC8* \[[@CR2]\]. Dysfunction of other genes causes 11--30% of cases of MODY and are defined as MODY-X \[[@CR3]\]. Previously, some of *GLIS3* gene polymorphisms have been shown to be associated with the development of MODY \[[@CR4]\].

The gene codes for a Krüppel-like zinc finger transcription factor that is located in a nuclear compartment of the cell and in the Golgi complex. GLIS3 expression in the embryo shows spatial and temporal dependence on embryogenesis stages, whereas in adults it is tissue-specific and depends on cell type. GLIS3 expression occurs mainly in kidneys and in the pancreas, thyroid, thymus, uterus, ovaries, brain, and lungs \[[@CR5]\].

GLIS3 plays a critical role in the regulation of many physiological processes (insulin gene expression, β-cell formation, thyroid hormone biosynthesis, spermatogenesis, and kidney function) \[[@CR6]\]. It is one of the most differentially expressed genes in β-cells between healthy people and patients with DM2 \[[@CR7]\]. *GLIS3* mRNA expression is decreased by 50% in pancreatic islets of patients with DM2 in comparison with healthy people \[[@CR8]\]. It is known that mutations in GLIS3-binding sites of the *INS* gene promoter cause neonatal diabetes \[[@CR9]\]. All single-nucleotide variants (SNVs) of *GLIS3* that have been associated with DM1 and DM2 in genome-wide association studies are located in noncoding regions in contrast to the SNVs associated with neonatal diabetes. It is thought that these substitutions may regulate *GLIS3* gene expression. Probably, they are associated with β-cells' ability to respond to immune, viral, and metabolic stressors and have made the *GLIS3* gene a common member of the genetic risk factors of DM1 and DM2 \[[@CR10]\].

The aim of this study was identification of probably pathogenic variants of *GLIS3* in patients with MODY using a whole-exome sequencing approach and estimation of the frequency of rs806052, rs143051164, and rs149840771 in a Russian population and DM2 patients.

Main text {#Sec2}
=========

Methods {#Sec3}
-------

The study protocol was approved by the local Ethics Committee of the Institute of Internal and Preventive Medicine (a branch of the Institute of Cytology and Genetics, the Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia). Written informed consent to be examined and to participate in the study was obtained from each patient. For individuals younger than 18 years, the informed consent was signed by a parent or legal guardian.

The inclusion criteria were as follows: signing informed consent for participation in the study, a verified diagnosis of diabetes, a debut of the disease for probands at the age of 35 years and earlier, the absence of obesity, absence of pancreas islet cell antibodies, absence of glutamic acid decarboxylase antibodies, sufficient secretion of β-cells, absence of necessity of insulin therapy, and the absence of ketoacidosis at the onset of the disease. The following exclusion criteria were applied: a history of tuberculosis of lungs or other organs or of infection with the human immunodeficiency virus, an infectious disease caused by a hepatitis B virus or a hepatitis C virus that requires antiviral treatment, substance abuse or alcoholism for 2 years before the examination.

In the first phase of the study, whole-exome sequencing was performed on 21 probands with a MODY phenotype and five of their first-degree relatives (three with a MODY phenotype) for analysis of the *GLIS3* mutation spectrum. A total of 26 patients underwent a full medical examination; a biochemical blood test; determination of HbA1c, C-peptide, anti-GAD (glutamic acid decarboxylase) antibodies, pancreas islet cell antibodies (ICA), thyroid status, and microalbuminuria; abdominal and renal ultrasonography; real-time continuous glucose monitoring with Medtronic Paradigm MMT-722; and genetic tests. Genomic DNA was isolated from leukocytes of venous blood by phenol--chloroform extraction \[[@CR11]\]. Quality of the extracted DNA was assessed on a capillary electrophoresis system (Agilent 2100 Bioanalyzer; Agilent Technologies Inc., USA). Sequencing of the first group of samples (11 patients) was conducted on an Ion Proton instrument (Thermo Fisher Scientific). Whole-exome libraries were prepared with the AmpliSeq Exome Kit (Thermo Fisher Scientific). The data-processing pipeline included mapping the reads to the reference human genome (GRCh37) using the Burrows--Wheeler Aligner (BWA) v.0.7.12 software followed by SNV calling performed by means of GATK. SNV annotation was conducted in the IonReporter 4.0 software. The average depth of coverage was 30×. Sequencing in the second group of patients (15 individuals, respectively) was carried out on an Illumina HiSeq 1500 instrument (Illumina, San Diego, CA, USA). The enrichment and library preparation were performed using the SureSelectXT Human All Exon V5 + UTRs Kit. Reads were mapped to the reference human genome (GRCh37) in the BWA v.0.7.12 software. PCR duplicates were removed by means of the Picard software. A search for polymorphisms was conducted using the Genome Analysis Toolkit v.3.3 package by the procedure for local remapping of short insertions/deletions and recalibration of the read quality. The depth of coverage was from 34× to 53×.

In sequenced groups, we filtered sequence variants if they were present in 10 or more variant reads with a quality score ≥ 30. In this study, the search for polymorphic sites covered known MODY genes and *GLIS3*. A comparison of the detected substitutions was performed with a number of specialized databases: the 1000 Genomes Project (<http://www.1000genomes.org/>), dbSNP database (<https://www.ncbi.nlm.nih.gov/SNP/>), and ClinVar (<http://clinvar.com/>). We selected the spectrum of rare sequence variants in MODY genes (nonsynonymous, alternative splice site, and coding indels variants) and only nonsynonymous SNVs for common substitutions. Rare variants were selected if their minor allele frequency (MAF) was ≤ 1% in the 1000 Genomes database and if they were present in the dbSNP database.

The possible functional and significant effects of SNVs were assessed by means of in silico tools PolyPhen-2 v2.2.5 (<http://genetics.bwh.harvard.edu/pph2/dokuwiki/about>), SIFT (<http://sift.jcvi.org/>), and PROVEAN (<http://provean.jcvi.org/index.php>). Web services PolyPhen-2 v.2.2.5 and Provean/SIFT predict a possible impact of an amino acid substitution on the structure and function of a human protein.

In the second phase of analysis, we selected only the functional variants with MAF \< 0.5% and a potential pathogenic effect: rs806052, rs143051164, and rs149840771. In most cases, the MODY-causing SNVs are rare variants with low MAFs and cannot be highly distributed in the population; therefore, we focused on these substitutions. Verification for rs806052, rs143051164, and rs149840771 was performed by Sanger sequencing and oligonucleotides primers for SNVs were designed in the Primer-Blast software (<https://www.ncbi.nlm.nih.gov/tools/primer-blast/>). The oligonucleotides are shown in Additional file [1](#MOESM1){ref-type="media"}. These SNVs were tested by real-time PCR (Additional file [1](#MOESM1){ref-type="media"}) in 564 randomly selected individuals (Caucasians in Russia), in 188 patients with DM2, and in 126 patients with a MODY phenotype (Table [1](#Tab1){ref-type="table"}).Table 1Demographic characteristics of the tested individualsCaucasian populationType 2 diabetes mellitusMODYNumber564188126Age, years45--6945--691--38Mean age ± SD, years54.2 ± 0.459.0 ± 6.723.8 ± 2.5*SD* standard deviation

The population group included in the analysis was selected from a survey of the population interviewed within the framework of the HAPIEE project \[[@CR12]\], Novosibirsk, Russia (9360 participants, aged 45--69 years, men 50%, Caucasians 97%). A total of 564 randomly selected patients (some may have diabetes, age 54.2 ± 0.4, mean ± SD) were included.

The DM2 group consisted of 68 women and 87 men (age 59.0 ± 6.7, mean BMI among men: 31, women: 32). The DM2 sample was randomly selected from the HAPIEE participants \[[@CR12]\]. We used the criteria of the American Diabetes Association \[[@CR13]\] for the diagnosis of DM2.

A total of 126 patients with a MODY phenotype (age 23.8 ± 2.6) underwent the same medical examination as described above.

Rs806052 was genotyped by the TaqMan SNP assay (Synthol, Russia) and StepOnePlus 7900HT Real-Time PCR System (Thermo Fisher Scientific, USA). Rs143051164 and rs149840771 were genotyped by the TaqMan SNP assay (BioLabMix, Russia) and StepOnePlus 7900HT Real-Time PCR System (Thermo Fisher Scientific, USA).

Statistical data processing was performed in the IBM SPSS Statistics 23.0 software. Validity of differences in allele prevalence between groups was determined using the χ^2^ criterion. Differences were considered statistically significant at p \< 0.05.

Results {#Sec4}
-------

The spectrum of *GLIS3* gene polymorphism in patients with a MODY phenotype was identified by the whole-exome sequencing method. During this analysis, 15 SNV were found (Table [2](#Tab2){ref-type="table"}). Most of these SNVs are common variants and located in noncoding exon--intron boundaries. Rs806052 is located in a DNA-binding domain, rs143051164 in the region of potential interaction with proteins ISL1, ITCH, Smurf 2, Smurf 1, DNAJA1, and HIPK3 \[[@CR14]\], and rs149840771 is located near the transactivation C-terminal domain of the GLIS3 protein.Table 2The *GLIS3* gene polymorphism spectrum in patients with a MODY phenotype in RussiaChromosome: positionLocalizationaa or nucleotide changesSNVZygosityClinical significance (ClinVar)MAF from 1000Gchr9:3828379Exon 11p.Leu896Phe/c.2686C\>Trs76094493HeterozygousLikely benignA = 0.04chr9:3829212Intron 10T\>Crs7029652HeterozygousNAC = 0.14chr9:3855963Intron 9delArs397766987HeterozygousNAA = 0.36chr9:3879646Intron 7G\>Ars17692969HeterozygousNAA = 0.026chr9:3879693Intron 7T\>Crs4740742HeterozygousC = 0.09chr9:3898723Exon 6p.Arg699His/c.2096G\>Ars149840771HeterozygousNAT = 0.0002chr9:3932283Intron 6C\>Grs535978Heterozygous, homozygous GGNAG = 0.40chr9:3932521Intron 5C\>Trs587571HeterozygousNAT = 0.04chr9:3937255Intron 4T\>Ars676935HeterozygousNAA = 0.37chr9:3937288Intron 4G\>Ars10974212HeterozygousNAA = 0.32chr9:4118111Exon 4p.Pro456Gln/c.1367C\>Ars6415788Homozygous AAOtherG = 0.32chr9:4118208Exon 4p.Ser424Pro/c.1270T\>Crs806052Homozygous CCOtherA = 0.001chr9:4118634Exon 4p.Pro282Ala/c.844C\>Grs143051164HeterozygousUncertain significance alleleC = 0.0004chr9:4285986Intron 2G\>Crs10758591HeterozygousNAC = 0.34chr9:4298537Intron 1G\>Ars12340657HeterozygousNAA = 0.23*NA* not available, *MAF* minor allele frequency

The GG rs806052 (c.1270T\>C) genotype in the homozygous form was identified in our group of Caucasians in Russia and in all patients with MODY (Table [3](#Tab3){ref-type="table"}). This variant is present with a rare allele in one patient with MODY, but after validation it was not confirmed. Nevertheless, we tested this SNV in our groups because it had been found in patients with DM2 and seemed interesting \[[@CR15]\]. In the DM2 group, a heterozygous rs806052 variant was identified in one male patient without a family history of diabetes mellitus. Prevalence rates of rs806052, rs143051164, and rs149840771 are presented in Table [3](#Tab3){ref-type="table"}.Table 3Prevalence of rs806052, rs143051164, and rs149840771 in the tested samplesGenotypesCaucasian populationMODYType 2 diabetes mellitusrs806052 GG, % (n)100 (476)100 (96)99.7 (171) AG, % (n)0 (0)0 (0)0.3 (1) AA, % (n)0 (0)0 (0)0 (0)rs143051164 GG, % (n)99.7 (561)99.6 (125)99.7 (187) GC, % (n)0.3 (3)0.4 (1)0.3 (1) CC, % (n)0 (0)0 (0)0 (0)rs149840771 CC, % (n)99.7 (560)99.6 (125)100 (188) CT, % (n)0.3 (4)0.4 (1)0 (0) TT, % (n)0 (0)0 (0)0 (0)

Frequencies of rs806052, rs143051164, and rs149840771 in the Russian population are close to the ones described in databases.

Prevalence of rare allele C rs143051164 (c.844C\>G) in the Caucasian population was 0.003, in the MODY group 0.004, and in the DM2 group 0.003. In the Caucasian group, a heterozygous genotype was identified in three individuals without carbohydrate metabolism disorders and without a family history of diabetes mellitus.

Prevalence of rare allele T rs149840771 (c.2096G\>A) in the Caucasian population was 0.003, and in the MODY group, 0.004. In the DM2 group, the rare allele of rs149840771 was not identified.

Discussion {#Sec5}
----------

A number of studies have shown that *GLIS3* plays a role in the regulation of at least four different processes associated with development and normal functioning of the pancreas. Regulation of differentiation of pancreatic islets at an early stage of embryogenesis via activation of transcription factor neurogenin 3 (Ngn3) is involved in β-cell development. Impairment of this process leads to neonatal diabetes. Control of β-cell proliferation under stressful conditions in adults by the regulation of cyclin D2 (CCND2) expression is important for a compensatory increase in β-cell mass during obesity. Impairment of this regulatory step causes the development of DM2. Two more processes---β-cell apoptosis regulation by activation of SRp55 splicing factor expression and regulation of insulin gene expression---can perform a major function at all stages of organismal development \[[@CR16]\].

There are more than 10 genes, and many variants of these genes have been found to be associated with diabetes phenotypes. These data allowed us to suppose that substitutions in exons of *GLIS3* are associated with MODY-X or are phenotype modifiers in DM2.

No differences were identified in allele frequencies of the analyzed SNV of GLIS3 in patients with confirmed MODY and the other two groups (patients with DM2 and the Caucasian population). We did not find any novel mutation in coding and splicing site regions of the *GLIS3* gene.

Considering the lack of data on a correlation between rare exon SNVs rs806052, rs143051164, and rs149840771 of the GLIS3 gene and the development of MODY and DM2 in this study, we suppose that these variants are not associated with these pathological phenotypes in Russia. It seems reasonable to analyze a noncoding part of this gene by searching for SNVs associated with different forms of diabetes mellitus.

Limitations {#Sec6}
===========

The *GLIS3* gene mutation spectrum did not show substantial differences among the different tested samples. Whole-exome sequencing did not reveal new SNVs in *GLIS3* of patients with MODY in Russia.

The results of genotyping of the Caucasian group and patients with carbohydrate metabolism disorders allow us to suggest that rare SNVs rs806052, rs143051164, and rs149840771 of the *GLIS3* gene do not take part in the pathogenesis of MODY and DM2 in Russia. One of the limitations of our study is the low sample size. Another limitation is analysis of SNVs only in the coding region of *GLIS3* because there are some SNVs in the noncoding region that are associated with DM1 and DM2 \[[@CR10]\].

Additional file
===============

 {#Sec7}

**Additional file 1.** Genetic analysis of rs806052, rs143051164, and rs149840771. Sequencing, RT-PCR conditions, and in silico analysis for the GLIS3 gene.
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